MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN

Fan,Wenxing; Huang,Jie; Xiao,Hua; Liang,Zhang

doi:10.3892/mmr.2016.5101

MicroRNA-22 is downregulated in clear cell renal cell carcinoma, and inhibits cell growth, migration and invasion by targeting PTEN

Authors:
- Wenxing Fan
- Jie Huang
- Hua Xiao
- Zhang Liang
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Department of Science and Technology, Kunming Medical University, Kunming, Yunnan 650500, P.R. China
Published online on: April 11, 2016 https://doi.org/10.3892/mmr.2016.5101
Pages: 4800-4806

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)-22 has previously been reported to be frequently downregulated in certain types of cancer. The present study examined the expression and effects of miR-22 in renal cell carcinoma (RCC). The results indicated that miR‑22 was downregulated in tumor tissue from patients with RCC. In addition, lower miR‑22 expression levels were associated with histological grade, tumor stage and lymph node metastasis. Following transfection of RCC cells with miR‑22, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, cell migration, cell invasion and luciferase assays, and western blotting were conducted. The results demonstrated that miR‑22 was able to inhibit cell proliferation, migration and invasion in 786‑O and A498 cells. Furthermore, the results indicated that miR‑22 may directly target phosphatase and tensin homolog (PTEN) in RCC. In conclusion, the present study suggested that the miR-22/PTEN axis may be considered a novel therapeutic target in RCC. These findings may be beneficial for the development of an effective therapy against RCC.

View Figures

View References

1	White NM and Yousef GM: MicroRNAs: Exploring a new dimension in the pathogenesis of kidney cancer. BMC Med. 8:652010. View Article : Google Scholar : PubMed/NCBI
2	Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y and Dahiya R: MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res. 71:6208–6219. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lian JH, Wang WH, Wang JQ, Zhang YH and Li Y: MicroRNA-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/Akt signaling pathway. Asian Pac J Cancer Prev. 14:5017–5021. 2013. View Article : Google Scholar : PubMed/NCBI
4	Yu ZH, Zhang Q, Wang YD, Chen J, Jiang ZM, Shi M, Guo X, Qin J, Cui GH, Cai ZM, et al: Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Asian Pac J Cancer Prev. 14:3729–3734. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jiang Z, Chu PG, Woda BA, Liu Q, Balaji KC, Rock KL and Wu CL: Combination of quantitative IMP3 and tumor stage: A new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 14:5579–5584. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wu D, Li M, Wang L, Zhou Y, Zhou J, Pan H and Qu P: MicroRNA-145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma. Mol Med Rep. 10:393–398. 2014.PubMed/NCBI
7	Li M, Wang Y, Song Y, Bu R, Yin B, Fei X, Guo Q and Wu B: MicroRNAs in renal cell carcinoma: A systematic review of clinical implications (Review). Oncol Rep. 33:1571–1578. 2015.PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Dang Y, Zhao S, Qin Y, Han T, Li W and Chen ZJ: MicroRNA-22-3p is down-regulated in the plasma of Han Chinese patients with premature ovarian failure. Fertil Steril. 103:802–807. 2015. View Article : Google Scholar : PubMed/NCBI
10	Huang ZP and Wang DZ: MiR-22 in cardiac remodeling and disease. Trends Cardiovasc Med. 24:267–272. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
12	Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar :
13	Kwak PB, Iwasaki S and Tomari Y: The microRNA pathway and cancer. Cancer Sci. 101:2309–2315. 2010. View Article : Google Scholar : PubMed/NCBI
14	Chen X, Bo L, Zhao X and Chen Q: MicroRNA-133a inhibits cell proliferation, colony formation ability, migration and invasion by targeting matrix metallopeptidase 9 in hepatocellular carcinoma. Mol Med Rep. 11:3900–3907. 2015.PubMed/NCBI
15	Eacker SM, Dawson TM and Dawson VL: Understanding microRNAs in neurodegeneration. Nat Rev Neurosci. 10:837–841. 2009.PubMed/NCBI
16	Li B, Song Y, Liu TJ, Cui YB, Jiang Y, Xie ZS and Xie SL: MiRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol Rep. 29:1932–1938. 2013.PubMed/NCBI
17	Guo MM, Hu LH, Wang YQ, Chen P, Huang JG, Lu N, He JH and Liao CG: MiR-22 is down-regulated in gastric cancer, and its overexpression inhibits cell migration and invasion via targeting transcription factor Sp1. Med Oncol. 30:5422013. View Article : Google Scholar : PubMed/NCBI
18	Li J, Liang S, Yu H, Zhang J, Ma D and Lu X: An inhibitory effect of miR-22 on cell migration and invasion in ovarian cancer. Gynecol Oncol. 119:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Yang Y, Yang T, Liu Y, Li A, Fu S, Wu M, Pan Z and Zhou W: MicroRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 103:1215–1220. 2010. View Article : Google Scholar : PubMed/NCBI
20	Ling B, Wang GX, Long G, Qiu JH and Hu ZL: Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI
21	Tao J, Lu Q, Wu D, Li P, Xu B, Qing W, Wang M, Zhang Z and Zhang W: microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells. Oncol Rep. 25:1721–1729. 2011.PubMed/NCBI
22	Wang X, Yu H, Lu X, Zhang P, Wang M and Hu Y: MiR-22 suppresses the proliferation and invasion of gastric cancer cells by inhibiting CD151. Biochem Biophys Res Commun. 445:175–179. 2014. View Article : Google Scholar : PubMed/NCBI
23	Rizvi MM, Alam MS, Mehdi SJ, Ali A and Batra S: Allelic loss of 10q23.3, the PTEN gene locus in cervical carcinoma from northern indian population. Pathol Oncol Res. 18:309–313. 2012. View Article : Google Scholar
24	Cheng T, Zhang JG, Cheng YH, Gao ZW and Ren XQ: Relationship between PTEN and Livin expression and malignancy of renal cell carcinomas. Asian Pac J Cancer Prev. 13:2681–2685. 2012. View Article : Google Scholar : PubMed/NCBI
25	Gu J, Tamura M and Yamada KM: Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways. J Cell Biol. 143:1375–1383. 1998. View Article : Google Scholar : PubMed/NCBI
26	Brenner W, Färber G, Herget T, Lehr HA, Hengstler JG and Thüroff JW: Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer. 99:53–57. 2002. View Article : Google Scholar : PubMed/NCBI
27	Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X and Wu H: PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA. 96:6199–6204. 1999. View Article : Google Scholar : PubMed/NCBI
28	Hager M, Haufe H, Kemmerling R, Mikuz G, Kolbitsch C and Moser PL: PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology. 39:482–485. 2007. View Article : Google Scholar : PubMed/NCBI